Developing story · 2 episodes · 10 Oct to 20 Oct
AI Biotech Expands Beyond Protein Folding Limits
The saga tracks the evolution of AI in biotechnology, beginning with debates over AlphaFold's protein folding limitations and expanding into broader applications like rare-disease drug discovery. The latest developments show the field shifting from theoretical constraints to practical market growth in virtual labs and specialized therapeutics.
-
Medical AI expands into rare‑disease drug discovery and virtual lab markets
DeepMind’s AlphaFold has predicted more than 200 million protein structures, giving AI‑driven drug discovery startups a large data foundation. Recursion Pharmaceuticals, a US biotech, reports…
1 source -
DeepMind and Biohub debate AlphaFold’s limits in protein folding
Google DeepMind’s Pushmeet Kohli and Biohub’s Sal Candido discussed why AlphaFold’s breakthrough in protein structure prediction did not fully solve biology’s challenges. They argued that scaling…
1 source
Who and what
Google DeepMindBiohubDeepMindRecursion PharmaceuticalsIsomorphic LabsNovartisEli LillyKeymakrAlphaFoldAlphaFold 2Pushmeet KohliSal Candido